Literature DB >> 15150657

Experience with platinum-based and high-dose chemotherapy in patients with gestational trophoblastic disease: possible implications for future management.

Maurie Markman1.   

Abstract

PURPOSE: Despite the similarities between the chemotherapeutic management of advanced gestational trophoblastic disease (GTD) and ovarian germ cell tumors, important differences exist between the malignancies, particularly in the use of cisplatin.
METHODS: Three patients with persistent or recurrent GTD cared for at the Cleveland Clinic received a high-dose chemotherapy program (with stem cell support), one as management for etoposide-associated acute leukemia resulting from her "standard dose" treatment program.
RESULTS: While the indications for use of a dose-intensive strategy, and the ultimate clinical course, differed in the three patients, collectively these cases raise relevant questions regarding optimal management of high risk and recurrent GTD.
CONCLUSION: The experience represented in this report support the earlier use of cisplatin-based chemotherapy in the management of high-risk and recurrent GTD, and the possible administration of a high-dose chemotherapy program in the rare patient who recurs following "standard dose" platinum-based treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15150657     DOI: 10.1007/s00432-004-0568-5

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  27 in total

Review 1.  Epipodophyllotoxin-related leukemia. Identification of a new subset of secondary leukemia.

Authors:  J A Whitlock; J P Greer; J N Lukens
Journal:  Cancer       Date:  1991-08-01       Impact factor: 6.860

2.  Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vinblastine, bleomycin, and cisplatin.

Authors:  D M Gershenson; J J Kavanagh; L J Copeland; G Del Junco; A Cangir; P B Saul; C A Stringer; C L Edwards; J T Wharton
Journal:  Cancer       Date:  1986-05-01       Impact factor: 6.860

3.  High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables.

Authors:  J Beyer; A Kramar; R Mandanas; W Linkesch; A Greinix; J P Droz; J L Pico; A Diehl; C Bokemeyer; H J Schmoll; C R Nichols; L H Einhorn; W Siegert
Journal:  J Clin Oncol       Date:  1996-10       Impact factor: 44.544

4.  High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults.

Authors:  J P Lotz; T André; R Donsimoni; C Firmin; C Bouleuc; H Bonnak; Z Merad; A Esteso; J Gerota; V Izrael
Journal:  Cancer       Date:  1995-02-01       Impact factor: 6.860

5.  Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin.

Authors:  D M Gershenson; M Morris; A Cangir; J J Kavanagh; C A Stringer; C L Edwards; E G Silva; J T Wharton
Journal:  J Clin Oncol       Date:  1990-04       Impact factor: 44.544

6.  High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.

Authors:  W Siegert; J Beyer; I Strohscheer; H Baurmann; H Oettle; J Zingsem; R Zimmermann; C Bokemeyer; H J Schmoll; D Huhn
Journal:  J Clin Oncol       Date:  1994-06       Impact factor: 44.544

7.  Vinblastine, bleomycin, and cisplatin in malignant germ cell tumors of the ovary.

Authors:  M H Taylor; A D Depetrillo; A R Turner
Journal:  Cancer       Date:  1985-09-15       Impact factor: 6.860

8.  Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors.

Authors:  C Kollmannsberger; J Beyer; J P Droz; A Harstrick; J T Hartmann; P Biron; A Fléchon; P Schöffski; M Kuczyk; H J Schmoll; L Kanz; C Bokemeyer
Journal:  J Clin Oncol       Date:  1998-10       Impact factor: 44.544

Review 9.  Cytogenetic heterogeneity in t(11;19) acute leukemia: clinical, hematological and cytogenetic analyses of 48 patients--updated published cases and 16 new observations.

Authors:  J L Huret; A Brizard; R Slater; C Charrin; M F Bertheas; F Guilhot; K Hählen; W Kroes; E van Leeuwen; E V Schoot
Journal:  Leukemia       Date:  1993-02       Impact factor: 11.528

10.  PEBA regimen (cisplatin, etoposide, bleomycin, and adriamycin) in the treatment of drug-resistant choriocarcinoma.

Authors:  L P Chen; S M Cai; J X Fan; Z T Li
Journal:  Gynecol Oncol       Date:  1995-02       Impact factor: 5.482

View more
  1 in total

1.  High-dose chemotherapy with autologous peripheral blood stem cell transplantation for choriocarcinoma: A case report and literature review.

Authors:  Eiko Yamamoto; Kaoru Niimi; Kayo Fujikake; Tetsuya Nishida; Makoto Murata; Ayako Mitsuma; Yuichi Ando; Fumitaka Kikkawa
Journal:  Mol Clin Oncol       Date:  2016-09-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.